Sairy Hernandez - Concepedia

Author

Sairy Hernandez

Kindai University

Also Known As

S Hernandez, S. Hernandez, S. Hernández, S. R. Hernandez, S., Hernandez, Sairy Hernandez, Sandy C Hernandez

Publications

8.2K

Citations

H-Index

Concepts

All Affiliations

Kindai University National Taiwan University Hospital Roche (China)City of Hope Hôpital de la Croix-Rousse

About

Sairy Hernandez is an author at Kindai University specializing in cancer therapeutics, hepatology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	720
2	Hepatology	5	5	720
3	Pathology	5	5	720
4	Health Sciences	2	2	397
5	Immunology	1	1	116

Sairy Hernandez

Publications

8.1K

Citations

H-Index

Page 1

	Year	Citations
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma Richard S. Finn, Shukui Qin, Masafumi Ikeda, New England Journal of Medicine	2020	6.8K
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial Peter R. Galle, Richard S. Finn, Shukui Qin, The Lancet Oncology Patient-reported OutcomesHepatologyMedicineClinical TrialsPathology	2021	362
IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC) Ann‐Lii Cheng, S. Qin, Masafumi Ikeda, Annals of Oncology Ph Iii StudyHepatologyMedicinePathologyPharmacotherapy	2019	191
Survival for Women and Men with AIDS George F. Lemp, A. Hirozawa, Judith B. Cohen, The Journal of Infectious Diseases	1992	125
Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study Shukui Qin, Zhenggang Ren, Yin‐Hsun Feng, Liver Cancer	2021	123
Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). Stacey Stein, Michael J. Pishvaian, Michael Sangmin Lee, Journal of Clinical Oncology ImmunologyLethal CancerPathologyPharmacotherapyImmunotherapeutics	2018	116
The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function Sairy Hernandez, Qing Jing, Rebecca Hong Thibodeau, Cell Reports	2018	108
Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma Andrew X. Zhu, Farshid Dayyani, Chia‐Jui Yen, Clinical Cancer Research	2022	107
Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial Riad Salem, Daneng Li, Nicolas Sommer, Cancer Medicine	2021	55
Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Peter R. Galle, Richard S. Finn, Shukui Qin, Journal of Clinical Oncology Patient-reported OutcomesClinical EndpointPathologyFirst-line TreatmentPharmacotherapy	2020	35

Page 1